Evidence map›Paper›PMID 39576456›Full record

ArticleInsights into imaging2024

Development and external evaluation of a self-learning auto-segmentation model for Colorectal Cancer Liver Metastases Assessment (COALA).

Jacqueline I Bereska, Michiel Zeeuw, Luuk Wagenaar, Håvard Bjørke Jenssen, Nina J Wesdorp, Delanie van der Meulen, Leonard F Bereska, Efstratios Gavves, Boris V Janssen, Marc G Besselink and 20 more

Abstract read
In one paragraph

Article in Insights into imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Jacqueline I Bereska *Cancer Center Amsterdam, Amsterdam, The Netherlands. j.i.bereska@amsterdamUMC.nl.ORCID http://orcid.org/0000-0002-2491-5833
Michiel Zeeuw *Cancer Center Amsterdam, Amsterdam, The Netherlands.
Luuk WagenaarCancer Center Amsterdam, Amsterdam, The Netherlands.
Håvard Bjørke JenssenOslo University Hospital, Department of Radiology and Nuclear Medicine, Oslo, Norway.
Nina J WesdorpCancer Center Amsterdam, Amsterdam, The Netherlands.
Delanie van der MeulenCancer Center Amsterdam, Amsterdam, The Netherlands.
Leonard F BereskaUniversity of Amsterdam, Video and Image Sense Lab, Amsterdam, The Netherlands.
Efstratios GavvesUniversity of Amsterdam, Video and Image Sense Lab, Amsterdam, The Netherlands.
Boris V JanssenCancer Center Amsterdam, Amsterdam, The Netherlands.
Marc G BesselinkCancer Center Amsterdam, Amsterdam, The Netherlands.
Henk A MarqueringCancer Center Amsterdam, Amsterdam, The Netherlands.
Jan-Hein T M van WaesbergheCancer Center Amsterdam, Amsterdam, The Netherlands.
Davit L AghayanOslo University Hospital, Department of Hepato-Pancreato-Biliary Surgery, Oslo, Norway.
Egidijus PelanisOslo University Hospital, Department of Hepato-Pancreato-Biliary Surgery, Oslo, Norway.
Janneke van den BerghCancer Center Amsterdam, Amsterdam, The Netherlands.
Irene I M NotaCancer Center Amsterdam, Amsterdam, The Netherlands.
Shira MoosCancer Center Amsterdam, Amsterdam, The Netherlands.
Gunter KemmerichOslo University Hospital, Department of Radiology and Nuclear Medicine, Oslo, Norway.
Trygve SyversveenOslo University Hospital, Department of Radiology and Nuclear Medicine, Oslo, Norway.
Finn Kristian KolrudOslo University Hospital, Department of Radiology and Nuclear Medicine, Oslo, Norway.
Joost HuiskensCancer Center Amsterdam, Amsterdam, The Netherlands.
Rutger-Jan SwijnenburgCancer Center Amsterdam, Amsterdam, The Netherlands.
Cornelis J A PuntAmsterdam UMC, University of Amsterdam, Department of Medical Oncology, Amsterdam, The Netherlands.
Jaap StokerCancer Center Amsterdam, Amsterdam, The Netherlands.
Bjørn EdwinOslo University Hospital, Department of Hepato-Pancreato-Biliary Surgery, Oslo, Norway.
Åsmund A FretlandOslo University Hospital, Department of Hepato-Pancreato-Biliary Surgery, Oslo, Norway.
Geert KazemierCancer Center Amsterdam, Amsterdam, The Netherlands.
Inez M VerpalenCancer Center Amsterdam, Amsterdam, The Netherlands. i.m.verpalen@amsterdamUMC.nl.
Pancreatobiliary and Hepatic Artificial Intelligence Research (PHAIR) consortium
Dutch Colorectal Cancer Group Liver Expert Panel

Funding

KWF Kankerbestrijding 14002/2021-2
6 · The paper itself

Abstract

objectivesTotal tumor volume (TTV) is associated with overall and recurrence-free survival in patients with colorectal cancer liver metastases (CRLM). However, the labor-intensive nature of such manual assessments has hampered the clinical adoption of TTV as an imaging biomarker. This study aimed to develop and externally evaluate a CRLM auto-segmentation model on CT scans, to facilitate the clinical adoption of TTV.

methodsWe developed an auto-segmentation model to segment CRLM using 783 contrast-enhanced portal venous phase CTs (CT-PVP) of 373 patients. We used a self-learning setup whereby we first trained a teacher model on 99 manually segmented CT-PVPs from three radiologists. The teacher model was then used to segment CRLM in the remaining 663 CT-PVPs for training the student model. We used the DICE score and the intraclass correlation coefficient (ICC) to compare the student model's segmentations and the TTV obtained from these segmentations to those obtained from the merged segmentations. We evaluated the student model in an external test set of 50 CT-PVPs from 35 patients from the Oslo University Hospital and an internal test set of 21 CT-PVPs from 10 patients from the Amsterdam University Medical Centers.

resultsThe model reached a mean DICE score of 0.85 (IQR: 0.05) and 0.83 (IQR: 0.10) on the internal and external test sets, respectively. The ICC between the segmented volumes from the student model and from the merged segmentations was 0.97 on both test sets.

conclusionThe developed colorectal cancer liver metastases auto-segmentation model achieved a high DICE score and near-perfect agreement for assessing TTV. CRITICAL RELEVANCE STATEMENT: AI model segments colorectal liver metastases on CT with high performance on two test sets. Accurate segmentation of colorectal liver metastases could facilitate the clinical adoption of total tumor volume as an imaging biomarker for prognosis and treatment response monitoring. KEY POINTS: Developed colorectal liver metastases segmentation model to facilitate total tumor volume assessment. Model achieved high performance on internal and external test sets. Model can improve prognostic stratification and treatment planning for colorectal liver metastases.

Indexed as

Artificial intelligenceBiomarkersColorectal neoplasmsLiverTumor

Identifiers

PMID39576456
PMCPMC11584830

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.